Takeda Strikes $1.13 Billion Deal for Hutchmed Colorectal Cancer Treatment

Takeda will pay approximately $400 million upfront for the exclusive worldwide rights to Hutchmed’s fruquintinib, a tyrosine kinase inhibitor, outside of China.